Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Emmecell logo — Magnetic Cell Delivery Platform for Cell Therapy

Emmecell

Magnetic Cell Delivery Platform for Cell Therapy

United States Menlo Park, United States 11 employees Biotechnology, Health Care

General Information

Company Name Emmecell
Location United States Menlo Park, United States +1
Employees 11
Industries Biotechnology, Health Care
Social

Get notified when Emmecell moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Emmecell

Emmecell, a privately-held, clinical stage biotechnology company, is gaining attention in the field of cell-based therapies with their innovative magnetic cell delivery platform. Their lead product, EO2002, is designed to tackle corneal edema, a prevalent indication for corneal transplantation. By leveraging magnetic nanoparticles, Emmecell aims to improve the localization and integration of cell therapies into the target tissue, thus presenting a promising solution to a common healthcare challenge. In 2018, Emmecell expanded its reach with the establishment of Cell Manufacturing and Production LLC (CellMP), a subsidiary offering GMP manufacturing services in Menlo Park, CA. This strategic move not only enhances the company's capabilities but also positions them for potential growth in the biotechnology and healthcare industries. Although no recent investment details are available, Emmecell's focus on advancing cell-based therapies and strengthening their manufacturing capabilities demonstrates a forward-looking approach. Considering their pioneering technology and potential to address unmet medical needs, Emmecell presents an intriguing opportunity for venture capital firms seeking to invest in innovative biotechnology ventures.

Taxonomy: Ophthalmology, Cell Therapy, Nanotechnology, Magnetic Cell Delivery, Clinical Trials, cGMP Manufacturing

No funding data available for Emmecell yet.

Get notified when Emmecell raises funding

Emmecell Alternatives & Competitors

Emmecell vs
StemSight - Vision Unlimited
StemSight - Vision Unlimited Finland

Curing blindness with regenerative cell therapies.

Seed
16 employees
Biotechnology, Health Care
Emmecell vs
Aurion Biotech
Aurion Biotech United States

We're on a mission to cure blindness with our transformational platform of advanced therapies

Acquired
94 employees
Biopharma, Biotechnology
Compare Emmecell vs Aurion Biotech
Emmecell vs
Sarcura
Sarcura Austria

Powering New Possibles in Cell Therapy Manufacturing

Seed
11 employees
Biotechnology, Life Sciences

FAQ About Emmecell

Magnetic Cell Delivery Platform for Cell Therapy
Emmecell is headquartered in Menlo Park, United States.
Emmecell operates in the following industries: Biotechnology, Health Care.
Emmecell has approximately 11 employees.
Top alternatives and competitors to Emmecell include StemSight - Vision Unlimited, Aurion Biotech, Sarcura, RoslinCT, Cellares. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Emmecell and StemSight - Vision Unlimited are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Emmecell and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy